TY - JOUR
T1 - Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
AU - Dejaco, Christian
AU - Oppl, Bastian
AU - Monach, Paul
AU - Cuthbertson, David
AU - Carette, Simon
AU - Hoffman, Gary
AU - Khalidi, Nader
AU - Koening, Curry
AU - Langford, Carol
AU - McKinnon-Maksimowicz, Kathleen
AU - Seo, Philip
AU - Specks, Ulrich
AU - Ytterberg, Steven
AU - Merkel, Peter A.
AU - Zwerina, Jochen
N1 - Publisher Copyright:
© 2015, Public Library of Science. All rights reserved.
PY - 2015/3/26
Y1 - 2015/3/26
N2 - Introduction: Previous studies suggest a role for eotaxin-3, TARC/CCL17 and IgG4 in newly- diagnosed patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) with highly active disease. The role of these biomarkers in relapsing disease is unclear. Methods: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio were determined in serum samples from a longitudinal cohort of patients with EGPA (105 visits of 25 patients). Epidemiological, clinical and laboratory data were available for all visits. Results: At the first visit, 80%of patients were using glucocorticoids and 68%additional immunosuppressive drugs. Disease flares were seen at 18 visits. The median BVAS and BVAS/WG scores at time of relapse were 4 and 2, respectively. None of the biomarkers tested were useful to discriminate between active disease and remission. Patients treated with prednisone had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids irrespective of disease activity. Use of immunosuppressive agents was not associated with biomarker levels. Conclusions: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio do not clearly differentiate active and inactive disease in established EGPA. Defining biomarkers in EGPA remains a challenge especially during times of glucocorticoid use.
AB - Introduction: Previous studies suggest a role for eotaxin-3, TARC/CCL17 and IgG4 in newly- diagnosed patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) with highly active disease. The role of these biomarkers in relapsing disease is unclear. Methods: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio were determined in serum samples from a longitudinal cohort of patients with EGPA (105 visits of 25 patients). Epidemiological, clinical and laboratory data were available for all visits. Results: At the first visit, 80%of patients were using glucocorticoids and 68%additional immunosuppressive drugs. Disease flares were seen at 18 visits. The median BVAS and BVAS/WG scores at time of relapse were 4 and 2, respectively. None of the biomarkers tested were useful to discriminate between active disease and remission. Patients treated with prednisone had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids irrespective of disease activity. Use of immunosuppressive agents was not associated with biomarker levels. Conclusions: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio do not clearly differentiate active and inactive disease in established EGPA. Defining biomarkers in EGPA remains a challenge especially during times of glucocorticoid use.
UR - http://www.scopus.com/inward/record.url?scp=84926315973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926315973&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0121737
DO - 10.1371/journal.pone.0121737
M3 - Article
C2 - 25812008
AN - SCOPUS:84926315973
SN - 1932-6203
VL - 10
JO - PloS one
JF - PloS one
IS - 3
M1 - e0121737
ER -